A few short, informational videos about Trulicity
How to Use the Pen
Learn the key administration steps for delivering a dose of Trulicity.
Mechanism of Action
See how Trulicity was designed with patients in mind.
A Day in Max’s Life with Type 2 Diabetes
Follow along with Max as he faces some of the daily challenges of living with type 2 diabetes.
Trulicity in the Nursing Home Setting
See how Trulicity impacted protocols at Four Seasons Nursing Home.
Real patients- Real Experiences
Follow along as Linda and Clayton explain how Trulicity helps them face some of the daily challenges of living with type 2 diabetes.
Balancing Blood Glucose in Long-term Care
See how glucose-dependent Trulicity is an option for long-term care residents.
Questions healthcare professionals often ask about Trulicity
Trulicity offers 4 efficacious* doses.1
Dosing: Initiate at 0.75 mg subcutaneously once weekly. For additional glycemic control, dose can be increased to 1.5 mg once weekly. Then the 1.5 mg dose may be increased after ≥4 weeks to 3.0 mg once weekly. The 3.0 mg dose may be increased after ≥4 weeks to the maximum dose of 4.5 mg once weekly. *Trulicity 3.0 mg was not statistically significant vs Trulicity 1.5 mg on A1C change from baseline at 36 weeks.
- Trulicity [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
- Trulicity [Instructions for Use]. Indianapolis, IN: Lilly USA, LLC.
- Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26(4):287-296.
- Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13(5):418-425.
- Pabreja K, Mohd MA, Koole C, et al. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol. 2014;171(5):1114-1128.
- Data on file. Eli Lilly and Company; 2014, TRU20151210A.
- Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial [published correction appears in Lancet. 2014;384:1348]. Lancet. 2014;384:1349-1357.